The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial
Abstract
BACKGROUND: The Prostate Cancer Prevention Trial (PCPT) reported a decreased incidence of prostate cancer overall but an increase in the incidence of high-grade prostate cancer with finasteride compared with placebo. We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size. METHODS: Prostate biopsies with Gleason score 8-10 (n = 90, finasteride; n = 52, placebo) were examined histologically for hormonal effects, and those with Gleason score 7-10 (n = 282, finasteride; n = 244, placebo) were examined for pathologic surrogates of disease extent. Prostate volumes were measured at biopsy. Samples from radical prostatectomies (n = 222, finasteride; n = 306, placebo) were examined for tumor grade and extent, and, where possible, grades at biopsy and prostatectomy were compared between the groups. Logistic regression was used to analyze differences between treatment groups with respect to pathologic criteria. All statistical tests were two-sided. RESULTS: Degenerative hormonal changes in high-grade biopsies were equivalent between the finasteride and placebo groups, but prostate volumes were lower in the finasteride group (median = 25.1 versus 34.4 cm3, P<.001). Pathologic surrogates for tumor extent were lower with finasteride than with placebo, including mean percentage of positive cores (34% versus 38%, P = .016), mean tumor linear extent (greatest [4.4 versus 4.8 mm, P = .19] and aggregate [7.6 versus 9.2 mm, P = .13]), bilaterality (22.8% versus 30.6%, P = .046), and perineural invasion (14.2% versus 20.3%, P = .07). Among patients who had prostatectomy, the finasteride-associated increase in high-grade disease (Gleason score > or = 7) at biopsy (42.7% finasteride versus 25.4% placebo, P<.001) was diminished at prostatectomy (46.4% finasteride versus 38.6% placebo, P = .10). Biopsy identified a greater proportion of patients with high-grade disease present at prostatectomy in the finasteride group than in the placebo group (69.7% versus 50.5%, P = .01). The rate of upgrading (from low-grade cancer at biopsy to high-grade cancer at prostatectomy) and pathologic stage at prostatectomy were similar in both groups. CONCLUSIONS: Effects of finasteride on prostate volume and selective inhibition of low-grade cancer, rather than effects on tumor morphology, may have contributed to the increase in high-grade cancers with finasteride in the PCPT. Although induction of high-grade cancer cannot be excluded, the results suggest that high-grade cancer was detected earlier and was less extensive in the finasteride group than in the placebo group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Self-citationSathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Histologic grading of prostate cancer: A perspective
Gleason, D. F. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90108-f · Cited by 1,034
Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer
Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj307 · Cited by 323
Self-citationIS LOW SERUM FREE TESTOSTERONE A MARKER FOR HIGH GRADE PROSTATE CANCER?
HOFFMAN, M. A., DeWOLF, W. C., & MORGENTALER, A. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67812-3 · Cited by 322
Stoner, E. (1994) · Urology · doi:10.1016/0090-4295(94)90068-x · Cited by 205
Ho, S. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10759 · Cited by 196
The Prevention of Prostate Cancer — The Dilemma Continues
Scardino, P. T. (2003) · New England Journal of Medicine · doi:10.1056/nejme038109 · Cited by 154
Djavan, B., Kadesky, K. T., Klopukh, B. V., et al. (1998) · European Urology · doi:10.1159/000019578 · Cited by 130
Cited by
Lippman, S. M., Klein, E. A., Goodman, P. J., Lucia, M. S., Thompson, I. M., Ford, L. G., Parnes, H. L., Minasian, L. M., Gaziano, J. M., Hartline, J. A., et al. (2009) · JAMA · doi:10.1001/jama.2008.864 · Cited by 2,122
Self-citationMolecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Cancer chemoprevention: a rapidly evolving field
Steward, W. P., & Brown, K. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.280 · Cited by 367
Medical treatments for male and female pattern hair loss
Rogers, N. E., & Avram, M. R. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.07.001 · Cited by 309
Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2134 · Cited by 293
Metadata
- Authors
- Lucia, M. S., Epstein, J. I., Goodman, P. J., Darke, A. K., Reuter, V. E., Civantos, F., Tangen, C. M., Parnes, H. L., Lippman, S. M., La Rosa, F. G., Kattan, M. W., Crawford, E. D., Ford, L. G., Coltman, C. A., & Thompson, I. M.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-09-11
- Volume
- 99
- Issue
- 18
- Pages
- 1375-1383
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2113720631
- Cited by
- 266
- References
- 17
- FWCI
- 31.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. https://app.cochat.ai/papers/10.1093/jnci/djm117
- The paper
- Lucia, M. S., Epstein, J. I., Goodman, P. J., Darke, A. K., Reuter, V. E., Civantos, F., Tangen, C. M., Parnes, H. L., Lippman, S. M., La Rosa, F. G., Kattan, M. W., Crawford, E. D., Ford, L. G., Coltman, C. A., & Thompson, I. M. (2007). Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djm117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.